BIM logo

bioMérieux S.A. Stock Price

ENXTPA:BIM Community·€12.6b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 5 Fair Values set on narratives written by author

BIM Share Price Performance

€108.30
5.30 (5.15%)
€123.46
Fair Value
€108.30
5.30 (5.15%)
12.3% undervalued intrinsic discount
€123.54
Fair Value
Price €108.30
AnalystConsensusTarget €123.54

BIM Community Narratives

AnalystConsensusTarget·
Fair Value €123.46 12.3% undervalued intrinsic discount

Continued Innovation And Market Leadership Will Ensure Future Success

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
€123.46
12.3% undervalued intrinsic discount
Revenue growth
7.1% p.a.
Profit Margin
13.26%
Future PE
27.15x
Share price in 2028
€149.29

Snowflake Analysis

Flawless balance sheet with moderate growth potential.

1 Risk
1 Reward

bioMérieux S.A. Key Details

€4.1b

Revenue

€1.8b

Cost of Revenue

€2.3b

Gross Profit

€1.9b

Other Expenses

€377.9m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
3.20
56.27%
9.17%
9.0%
View Full Analysis

About BIM

Founded
1963
Employees
14451
CEO
Pierre Boulud
WebsiteView website
www.biomerieux.com

bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR); BIOFIRE SPOTFIRE, a lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL, a rapid AST system; ETEST, a gradient method on culture media; BIOMERIEUX EPISEQ CS, a whole genome sequencing solution for epidemiologic monitoring; VIDAS, a specific marker of severe bacterial infections/sepsis; and Biomérieux vision suite, a software that provides information to support diagnosis and clinical decision making. It also provides culture media and associated instruments; ARGENE that provides PCR tests for diagnosing viral respiratory diseases; EMAG system and NUCLISENS extraction reagents for DNA and RNA extraction; GENE-UP and VERIFLOW for detection of microorganisms for the food industry; ETEST for manual measurement of minimum inhibitory concentration of an antibiotic; API and RAPIDEC CARBA NP for identification of bacteria and manual antimicrobial susceptibility testing; BIOBALL for quantitative microbiological quality control; CHEMUNEX, a microbiology instrument; ENDONEXT for detection of endotoxins; TEMPO for fluorescence counting of bacteria; and Hybiome, a CLIA technology, as well as lab consultancy service and training modules. The company was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.

Recent BIM News & Updates

Is bioMérieux (EPA:BIM) A Risky Investment?

Nov 10
Is bioMérieux (EPA:BIM) A Risky Investment?

Recent updates

No updates